Abstract
Fibrosis and excessive extracellular matrix production are characteristic features of lacrimal gland chronic GVHD (cGVHD). Tranilast (n-[3,4-anthoranilic acid]), used for fibrotic skin disease, inhibits transforming growth factor-β-induced matrix production. We conducted a non-randomized study comparing 8 patients (five men, three women; median age, 47 years) given topical tranilast with 10 patients (three men, seven women; median age, 37 years) receiving therapy with topical artificial tears, sodium hyaluronate and vitamin A for mild ocular cGVHD. The tranilast group instilled topical tranilast and artificial tears q.i.d., beginning the day of dry eye diagnosis. The ocular surface and tear dynamics of each patient were evaluated before hematopoietic stem cell transplant, at the onset of dry eye and after 3 months of treatment. At 3 months, the scores of the Rose Bengal test and Schirmer test with nasal stimulation had significantly improved in the tranilast group compared with that in the control group (P<0.05). Furthermore, although five control patients (50%) developed severe dry eye within the treatment period, only one tranilast-treated patient (12.5%) did; the rest still had mild dry eye (P<0.05). These results suggest the hypothesis that topical tranilast may effectively retard the progression of mild dry eye associated with cGVHD.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ogawa Y, Razzaque MS, Kameyama K, Hasegawa G, Shimmura S, Kawai M et al. Role of heat shock protein 47, a collagen-binding chaperone, in lacrimal gland pathology in patients with cGVHD. Invest Ophthalmol Vis Sci 2007; 48: 1079–1086.
Ogawa Y, Yamazaki K, Kuwana M, Mashima Y, Nakamura Y, Ishida S et al. A significant role of stromal fibroblasts in rapidly progressive dry eye in patients with chronic GVHD. Invest Ophthalmol Vis Sci 2001; 42: 111–119.
Prud'homme GJ . Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab Invest 2007; 87: 1077–1091.
Ogawa Y, Okamoto S, Wakui M, Watanabe R, Yamada M, Yoshino M et al. Dry eye after haematopoietic stem cell transplantation. Br J Ophthalmol 1999; 83: 1125–1130.
Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945–956.
The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007; 5: 75–92.
Tsubota K, Toda I, Yagi Y, Ogawa Y, Ono M, Yoshino K . Three different types of dry eye syndrome. Cornea 1994; 13: 202–209.
Qi W, Chen X, Twigg S, Polhill TS, Gilbert RE, Pollock CA . Tranilast attenuates connective tissue growth factor-induced extracellular matrix accumulation in renal cells. Kidney Int 2006; 69: 989–995.
Martin J, Kelly DJ, Mifsud SA, Zhang Y, Cox AJ, See F et al. Tranilast attenuates cardiac matrix deposition in experimental diabetes: role of transforming growth factor-beta. Cardiovasc Res 2005; 65: 694–701.
Yamada H, Tajima S, Nishikawa T . Tranilast inhibits collagen synthesis in normal, scleroderma and keloid fibroblasts at a late passage culture but not at an early passage culture. J Dermatol Sci 1995; 9: 45–47.
Taniguchi S, Yorifuji T, Hamada T . Treatment of linear localized scleroderma with the anti-allergic drug, tranilast. Clin Exp Dermatol 1994; 19: 391–393.
Soma J, Sato K, Saito H, Tsuchiya Y . Effect of tranilast in early-stage diabetic nephropathy. Nephrol Dial Transplant 2006; 21: 2795–2799.
Namazi MR, Soma J . Tranilast: a novel weapon against insulin resistance. Med Hypotheses 2005; 64: 1135–1137.
Ogawa Y, Kuwana M, Yamazaki K, Mashima Y, Yamada M, Mori T et al. Periductal a rea as the primary site for T-cell activation in lacrimal gland chronic graft-versus-host disease. Invest Ophthalmol Vis Sci 2003; 44: 1888–1896.
Acknowledgements
Supported by grants from the Japanese Ministry of Education, Science, Sports and Culture. #20592058.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ogawa, Y., Dogru, M., Uchino, M. et al. Topical tranilast for treatment of the early stage of mild dry eye associated with chronic GVHD. Bone Marrow Transplant 45, 565–569 (2010). https://doi.org/10.1038/bmt.2009.173
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2009.173
Keywords
This article is cited by
-
Advances in the ocular complications after hematopoietic stem cell transplantation
Annals of Hematology (2024)
-
The ocular graft-versus-host disease: the path from current knowledge to future managements
Eye (2023)
-
Pharmacological Treatment of Fibrosis: a Systematic Review of Clinical Trials
SN Comprehensive Clinical Medicine (2020)
-
Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT
Bone Marrow Transplantation (2019)
-
Prophylactic and therapeutic treatment of graft-versus-host disease in Japan
International Journal of Hematology (2015)